# A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

> **NCT07313761** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 349 (actual)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** Maridebart Cafraglutide

## Key facts

- **NCT ID:** NCT07313761
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2026-06-26
- **Final completion:** 2026-06-26
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07313761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07313761, "A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07313761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*